卵巢癌的大数据研究
摘要
<正>卵巢癌发病率居女性生殖系统恶性肿瘤第3位,死亡率居妇科恶性肿瘤之首。大数据通常是指用常规软件工具进行捕捉、管理和处理的数据集合,具有数据容量大、种类多和较高的科学价值。本文将对卵巢癌大数据研究资料进行归纳和整理。1流行病学特点在全球范围内,发达国家的卵巢癌发病率为
引文
[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA:Cancer J Clini,2015,65(2):87-108.
[2]Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA:Cancer J Clini,2017,67(1):7-30.
[3]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA:Cancer J Clini,2016,66(2):115-132.
[4]Mavaddat N,Peock S,Frost D,et al.Cancer risks for BRCA1and BRCA2 mutation carriers:results from prospective analysis of EMBRACE[J].J National Cancer Institute,2013,105(11):812-822.
[5]Risch HA,Mc Laughlin JR,Cole DE,et al.Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer[J].Am J Hum Genet,2001,68(3):700-710.
[6]Pal T,Permuth-Wey J,Betts JA,et al.BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases[J].Cancer,2005,104(12):2807-2816.
[7]Walsh T,Casadei S,Lee MK,et al.Mutations in 12 genes for inherited ovarian,fallopian tube,and peritoneal carcinoma identified by massively parallel sequencing[J].Pro National Acad Sci USA,2011,108(44):18032-18037.
[8]Wu X,Wu L,Kong B,et al.The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients[J].Int J Gynecol Cancer,2017,27(8):1650-1657.
[9]Alsop K,Fereday S,Meldrum C,et al.BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer:a report from the Australian Ovarian Cancer Study Group[J].J Clin Oncol,2012,30(21):2654-2663.
[10]Bolton KL,Chenevix-Trench G,Goh C,et al.Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer[J].JAMA,2012,307(4):382-390.
[11]Pennington KP,Walsh T,Harrell MI,et al.Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian,fallopian tube,and peritoneal carcinomas[J].Clin Cancer Res,2014,20(3):764-775.
[12]Kehoe S,Hook J,Nankivell M,et al.Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS):an open-label,randomised,controlled,noninferiority trial[J].Lancet,2015,386(9990):249-257.
[13]Vergote I,Trope CG,Amant F,et al.Neoadjuvant chemotherapy or primary surgery in stageⅢC orⅣovarian cancer[J].New Engl J Med,2010,363(10):943-953.
[14]van Meurs HS,Tajik P,Hof MH,et al.Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stageⅢC orⅣovarian cancer?an exploratory analysis of the european organisation for research and treatment of cancer 55971randomised trial[J].Eur J Cancer,2013,49(15):3191-3201.
[15]Harter P,du Bois A,Hahmann M,et al.Surgery in recurrent ovarian cancer:the Arbeitsgemeinschaft Gynaekologische Onkologie(AGO)DESKTOP OVAR trial[J].Ann Surg Oncol,2006,13(12):1702-1710.
[16]Dell'Anna T,Signorelli M,Benedetti-Panici P,et al.Systematic lymphadenectomy in ovarian cancer at second-look surgery:a randomised clinical trial[J].Br J Cancer,2012,107(5):785-792.
[17]Timmers PJ,Zwinderman K,Coens C,et al.Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer[J].Int J Gynecol Cancer,2010,20(7):1142-1147.
[18]Katsumata N,Yasuda M,Takahashi F,et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer:a phase 3,open-label,randomised controlled trial[J].Lancet,2009,374(9698):1331-1338.
[19]Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J].New Engl J Med,2006,354(1):34-43.
[20]Burger RA,Brady MF,Bookman MA,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].New Engl J Med,2011,365(26):2473-2483.
[21]Perren TJ,Swart AM,Pfisterer J,et al.A phase 3 trial of bevacizumab in ovarian cancer[J].New Engl J Med,2011,365(26):2484-2496.
[22]Aghajanian C,Blank SV,Goff BA,et al.OCEANS:a randomized,double-blind,placebo-controlled phaseⅢtrial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian,primary peritoneal,or fallopian tube cancer[J].J Clin Oncol,2012,30(17):2039-2045.
[23]Pujade-Lauraine E,Hilpert F,Weber B,et al.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer:the AURELIA open-label randomized phaseⅢtrial[J].J Clin Oncol,2014,32(13):1302-1308.
[24]Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].New Engl J Med,2012,366(15):1382-1392.
[25]Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer[J].New Engl J Med,2016,375(22):2154-2164.
[26]Eisen A,Lubinski J,Klijn J,et al.Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers:an international case-control study[J].J Clin Oncol,2005,23(30):7491-7496.
[27]Friebel TM,Domchek SM,Rebbeck TR.Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers:systematic review and meta-analysis[J].J National Cancer Institute,2014,106(6):dju091.
[28]Ducie J,Dao F,Considine M,et al.Molecular analysis of highgrade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma[J].Nat Commun,2017,8(1):990.
[2]Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA:Cancer J Clini,2017,67(1):7-30.
[3]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA:Cancer J Clini,2016,66(2):115-132.
[4]Mavaddat N,Peock S,Frost D,et al.Cancer risks for BRCA1and BRCA2 mutation carriers:results from prospective analysis of EMBRACE[J].J National Cancer Institute,2013,105(11):812-822.
[5]Risch HA,Mc Laughlin JR,Cole DE,et al.Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer[J].Am J Hum Genet,2001,68(3):700-710.
[6]Pal T,Permuth-Wey J,Betts JA,et al.BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases[J].Cancer,2005,104(12):2807-2816.
[7]Walsh T,Casadei S,Lee MK,et al.Mutations in 12 genes for inherited ovarian,fallopian tube,and peritoneal carcinoma identified by massively parallel sequencing[J].Pro National Acad Sci USA,2011,108(44):18032-18037.
[8]Wu X,Wu L,Kong B,et al.The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients[J].Int J Gynecol Cancer,2017,27(8):1650-1657.
[9]Alsop K,Fereday S,Meldrum C,et al.BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer:a report from the Australian Ovarian Cancer Study Group[J].J Clin Oncol,2012,30(21):2654-2663.
[10]Bolton KL,Chenevix-Trench G,Goh C,et al.Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer[J].JAMA,2012,307(4):382-390.
[11]Pennington KP,Walsh T,Harrell MI,et al.Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian,fallopian tube,and peritoneal carcinomas[J].Clin Cancer Res,2014,20(3):764-775.
[12]Kehoe S,Hook J,Nankivell M,et al.Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS):an open-label,randomised,controlled,noninferiority trial[J].Lancet,2015,386(9990):249-257.
[13]Vergote I,Trope CG,Amant F,et al.Neoadjuvant chemotherapy or primary surgery in stageⅢC orⅣovarian cancer[J].New Engl J Med,2010,363(10):943-953.
[14]van Meurs HS,Tajik P,Hof MH,et al.Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stageⅢC orⅣovarian cancer?an exploratory analysis of the european organisation for research and treatment of cancer 55971randomised trial[J].Eur J Cancer,2013,49(15):3191-3201.
[15]Harter P,du Bois A,Hahmann M,et al.Surgery in recurrent ovarian cancer:the Arbeitsgemeinschaft Gynaekologische Onkologie(AGO)DESKTOP OVAR trial[J].Ann Surg Oncol,2006,13(12):1702-1710.
[16]Dell'Anna T,Signorelli M,Benedetti-Panici P,et al.Systematic lymphadenectomy in ovarian cancer at second-look surgery:a randomised clinical trial[J].Br J Cancer,2012,107(5):785-792.
[17]Timmers PJ,Zwinderman K,Coens C,et al.Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer[J].Int J Gynecol Cancer,2010,20(7):1142-1147.
[18]Katsumata N,Yasuda M,Takahashi F,et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3weeks for advanced ovarian cancer:a phase 3,open-label,randomised controlled trial[J].Lancet,2009,374(9698):1331-1338.
[19]Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J].New Engl J Med,2006,354(1):34-43.
[20]Burger RA,Brady MF,Bookman MA,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].New Engl J Med,2011,365(26):2473-2483.
[21]Perren TJ,Swart AM,Pfisterer J,et al.A phase 3 trial of bevacizumab in ovarian cancer[J].New Engl J Med,2011,365(26):2484-2496.
[22]Aghajanian C,Blank SV,Goff BA,et al.OCEANS:a randomized,double-blind,placebo-controlled phaseⅢtrial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian,primary peritoneal,or fallopian tube cancer[J].J Clin Oncol,2012,30(17):2039-2045.
[23]Pujade-Lauraine E,Hilpert F,Weber B,et al.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer:the AURELIA open-label randomized phaseⅢtrial[J].J Clin Oncol,2014,32(13):1302-1308.
[24]Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].New Engl J Med,2012,366(15):1382-1392.
[25]Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer[J].New Engl J Med,2016,375(22):2154-2164.
[26]Eisen A,Lubinski J,Klijn J,et al.Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers:an international case-control study[J].J Clin Oncol,2005,23(30):7491-7496.
[27]Friebel TM,Domchek SM,Rebbeck TR.Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers:systematic review and meta-analysis[J].J National Cancer Institute,2014,106(6):dju091.
[28]Ducie J,Dao F,Considine M,et al.Molecular analysis of highgrade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma[J].Nat Commun,2017,8(1):990.